Glucose Monitoring Global Market – Forecast To 2029

Publishing Date : April, 2023
Report Code : HCMD0148
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Glucose Monitoring consists of products that are essential for measuring glucose levels in diabetes patients. With the projected rise in the aged population and awareness about diabetes conditions, the market is focused on growing with newer technology and improved products. According to IQ4I analysis, the glucose monitoring global market is expected to grow at a double digit CAGR from 2022 to 2029 reach $33,886.4 million by 2029.

Factors driving the Glucose Monitoring market are the global rise in the prevalence of diabetes, increasing demand for a less minimally invasive or non-invasive and point-of-care device; increasing R&D investments are driving the market growth, whereas, the growing diffusion of smart devices and digital platforms increasing compliance and management of diabetes is creating opportunities in the coming years. The high cost of the products, frequent product recalls and inadequate reimbursement is restraining the market growth. The stringent regulations for product approval, privacy concerns and safety issues are threats for the market growth.

Glucose Monitoring global market is segmented based on products, sample source, end-users and geography. The products market is divided into three segments, namely, Invasive, non-Invasive and lab-based glucose monitoring products. Among them, the Invasive glucose monitoring products segment accounted for the largest share in 2022 and is projected to grow at a double digit CAGR from 2022 to 2029 due to technological advancements, easy use, and patient-friendly nature of products. The non-invasive glucose monitoring segment is projected to grow at mid single digit CAGR from 2022 to 2029. The lab-based glucose monitoring segment contributed about XX% of the revenue and is projected to grow at low single digit CAGR from 2022 to 2029.

The Invasive glucose monitoring products are further segmented into self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) products, among them, the continuous glucose monitoring segment accounted for the largest share in 2022 and is expected to grow at high teen CAGR from 2022 to 2029 due to increasing awareness among patients and introduction of connected devices for integrated health management. The continuous glucose monitoring market is further sub-segmented into sensors and receivers & transmitters, among which, the sensors segment is the fastest-growing segment and is projected to grow at high single CAGR from 2022 to 2029.The Self glucose monitoring products are further sub-segmented into blood glucose monitors, blood glucose test strips, and lancets & others. The blood glucose testing strips segment accounted for the largest share in 2022 due development of no coding strips. Lancets and others contributed XX% revenue while the glucose meters contributed remaining XX% revenue in 2022.

Based on sample source the market is segmented into blood, urine and others. The blood segment accounted for the largest share in 2022 and is projected to grow at double digit CAGR from 2022 to 2029 due to the high accuracy of results. Other source-based glucose monitoring segment is the fastest-growing segment and is projected to grow at a strong double digit CAGR from 2022 to 2029 due to increased R&D investment, many products getting regulatory approved and ready to launch products.

Based on end-users the market is segmented into hospitals, private clinics, home care and ambulatory settings, among them, the home care segment accounted for the largest share in 2022 and is projected to grow at early teen CAGR from 2022 to 2029 due to the availability of over the counter (OTC) self blood glucose monitor and ease in operating these monitors and thereby reducing the frequent visits to hospitals or clinics for checking glucose levels. The hospitals segmented contributed XX% revenue in 2022 and is projected to grow at double digit CAGR from 2022 to 2029, the ambulatory settings contributed about XX% revenue in 2022 and is projected to grow at double digit CAGR from 2022 to 2029 and the private clinics segment contributed the remaining XX% revenue and is projected to grow at high single digit CAGR from 2022 to 2029.

Based on geography the market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of E.U.), Asia-Pacific (Japan, China, India and Rest of APAC) and the Rest of the World (Brazil, Middle East & others and Rest of Latin America). North America accounts for the largest market share in 2022 and the market is projected to grow at double digit CAGR from 2022 to 2029. The European market is the fastest growing region with early teen CAGR from 2022 to 2029 due to a steep rise in the aging population, advancement in technology, awareness of people about treatment options and favorable government policies.  The Asia-Pacific market is projected to grow at double digit CAGR from 2022 to 2029, while the RoW region is projected to grow at high single digit CAGR from 2022 to 2029.

Major players in the Glucose monitoring market include Abbott Laboratories (U.S.), Dexcom (U.S.), Roche (Switzerland), LifeScan (U.S.), Medtronic, Inc. (Ireland), PHC Holding (Ascensia) (Japan), Sinocare (China), Arkray (Japan), Bio-Rad Laboratories (U.S.), and i-Sens, Inc., (South Korea), etc.

 

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     THE GLOBAL RISE IN THE PREVALENCE OF DIABETES
        • 3.3.1.2     INCREASING DEMAND FOR MINIMALLY OR NON-INVASIVE AND POINT-OF-CARE DEVICES.
        • 3.3.1.3     INCREASING R & D INVESTMENTS
        • 3.3.1.4     GROWING DIFFUSION OF SMART DEVICES AND DIGITAL PLATFORMS INCREASING COMPLIANCE AND MANAGEMENT OF DIABETES
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     HIGH COST ASSOCIATED WITH THE PRODUCTS
        • 3.3.2.2     INADEQUATE REIMBURSEMENT
        • 3.3.2.3     PRODUCT RECALLS
        • 3.3.2.4     STRICT REGULATION OF GLUCOSE MONITORING DEVICES BY REGULATORY ORGANIZATIONS LIKE THE FDA AND OTHERS
        • 3.3.2.5     PRIVACY CONCERN AND SAFETY ISSUES IN CONNECTED DEVICES
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     U.S.
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     INDIA
      • 3.4.5     JAPAN
    • 3.5     REIMBURSEMENT SCENARIO
    • 3.6     PATENT ANALYSIS
    • 3.7     TECHNOLOGY ADVANCEMENTS
      • 3.7.1     NON-INVASIVE GLUCOSE MONITORING TECHNOLOGIES
        • 3.7.1.1     OPTICAL GLUCOSE MONITORING
        • 3.7.1.2     BREATH GLUCOSE MONITORING
        • 3.7.1.3     SWEAT GLUCOSE MONITORING
        • 3.7.1.4     PIPELINE OF NON-INVASIVE GLUCOSE MONITORING DEVICES
    • 3.8     FUNDING SCENARIO
    • 3.9     PORTER’S FIVE FORCE ANALYSIS
      • 3.9.1     THREAT OF NEW ENTRANTS
      • 3.9.2     THREAT OF SUBSTITUTES
      • 3.9.3     BARGAINING POWER OF SUPPLIERS
      • 3.9.4     BARGAINING POWER OF BUYERS
      • 3.9.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.10     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.10.1     GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
      • 3.10.2     SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
      • 3.10.3     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
    • 3.11     REGIONAL MARKET SHARE ANALYSIS
      • 3.11.1     NORTH AMERICA SELF MONITORING OF BLOOD GLUCOSE MARKET SHARE ANALSIS
      • 3.11.2     EUROPE SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
      • 3.11.3     ASIA-PACIFIC SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
      • 3.11.4     ROW SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
      • 3.11.5     NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
      • 3.11.6     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
      • 3.11.7     ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
      • 3.11.8     ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
    • 3.12     UNITS SOLD
      • 3.12.1     GLUCOSE TESTING STRIPS UNITS SOLD
      • 3.12.2     NUMBER OF CGM SENSORS SOLD
    • 3.13     MARKET PENETRATION ANALYSIS
      • 3.13.1     GLOBAL SMBG AND CGM MARKET PENETRATION ANALYSIS
      • 3.13.2     NORTH AMERICA SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.2.1     U.S. SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.2.2     REST OF N.A. SMBG AND CGM MARKET PENETRATION ANALYSIS
      • 3.13.3     EUROPE SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.3.1     GERMANY SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.3.2     FRANCE SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.3.3     ITALY SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.3.4     REST OF E.U. SMBG AND CGM MARKET PENETRATION ANALYSIS
      • 3.13.4     ASIA-PACIFIC SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.4.1     JAPAN SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.4.2     CHINA SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.4.3     INDIA SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.4.4     REST OF APAC SMBG AND CGM MARKET PENETRATION ANALYSIS
      • 3.13.5     REST OF THE WORLD SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.5.1     BRAZIL SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.5.2     MIDDLE EAST & OTHERS SMBG AND CGM MARKET PENETRATION ANALYSIS
        • 3.13.5.3     REST OF LATAM SMBG AND CGM MARKET PENETRATION ANALYSIS
  • 4     GLUCOSE MONITORING GLOBAL MARKET, BASED ON PRODUCTS
    • 4.1     INTRODUCTION
    • 4.2     INVASIVE GLUCOSE MONITORING
      • 4.2.1     SELF GLUCOSE MONITORING
        • 4.2.1.1     BLOOD GLUCOSE METER
        • 4.2.1.2     BLOOD GLUCOSE TESTING STRIPS
        • 4.2.1.3     LANCETS & OTHERS
      • 4.2.2     CONTINUOUS GLUCOSE MONITORING
        • 4.2.2.1     GLUCOSE SENSORS
        • 4.2.2.2     TRANSMITTERS AND RECEIVERS
    • 4.3     NON-INVASIVE GLUCOSE MONITORING
    • 4.4     LAB BASED GLUCOSE MONITORING
  • 5     GLUCOSE MONITORING GLOBAL MARKET, BASED ON SAMPLE SOURCE
    • 5.1     INTRODUCTION
    • 5.2     BLOOD-BASED GLUCOSE MONITORING
    • 5.3     URINE BASED GLUCOSE MONITORING
    • 5.4     OTHER SOURCES BASED GLUCOSE MONITORING
  • 6     GLUCOSE MONITORING GLOBAL MARKET, BASED ON END-USERS
    • 6.1     INTRODUCTION
    • 6.2     HOSPITALS
    • 6.3     HOME CARE
    • 6.4     PRIVATE CLINICS
    • 6.5     AMBULATORY SETTINGS
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     ITALY
      • 7.3.3     FRANCE
      • 7.3.4     REST OF EUROPE
    • 7.4     ASIA - PACIFIC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     REST OF ASIA-PACIFIC
    • 7.5     REST OF THE WORLD
      • 7.5.1     BRAZIL
      • 7.5.2     MIDDLE EAST & OTHERS
      • 7.5.3     REST OF LATIN AMERICA
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     AGREEMENTS, COLLABORATION & PARTNERSHIPS
    • 8.3     APPROVALS
    • 8.4     NEW PRODUCT LAUNCH
    • 8.5     OTHER DEVELOPMENTS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES, INC.
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     ARKRAY, INC.
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BIO-RAD LABORATORIES, INC.
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     DEXCOM, INC.
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     I-SENS, INC.
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     LIFESCAN
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     MEDTRONIC, PLC
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     PHC HOLDINGS (ASCENCIA DIABETES)
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     ROCHE HOLDINGS AG
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     SINOCARE INC.
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 2     SELF-MONITORING GLUCOSE TESTING STRIPS GLOBAL UNITS SOLD, BASED ON REGION, (2021-2029) (MN)
      • TABLE 3     CGM SENSORS GLOBAL UNITS SOLD, BASED ON REGION, (2021-2029) (MN)
      • TABLE 4     GLUCOSE MONITORING DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 5     INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 6     INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 7     SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 8     SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 9     BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 10     BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 11     LANCETS & OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 12     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 13     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 14     GLUCOSE SENSORS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 15     TRANSMITTER AND RECEIVER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 16     NON-INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 17     LAB BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 18     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED SAMPLE SOURCE, (2021-2029) ($MN)
      • TABLE 19     BLOOD-BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 20     URINE BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 21     OTHER SOURCES BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 22     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON END-USER, (2021-2029) ($MN)
      • TABLE 23     HOSPITAL GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 24     HOME CARE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 25     PRIVATE CLINICS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 26     AMBULATORY SETTING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 27     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 28     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 29     NORTH AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 30     NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 31     NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 32     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
      • TABLE 33     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 34     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 35     U.S. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 36     REST OF N. A. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 37     EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 38     EUROPE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 39     EUROPE SELF BLOOD GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 40     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 41     EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
      • TABLE 42     EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 43     EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 44     GERMANY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 45     ITALY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 46     FRANCE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 47     REST OF E.U. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 48     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 49     ASIA-PACIFIC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 50     ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 51     ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 52     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
      • TABLE 53     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 54     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 55     JAPAN INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 56     CHINA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 57     INDIA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 58     REST OF APAC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 59     ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 60     ROW INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 61     ROW SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 62     ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 63     ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
      • TABLE 64     ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 65     ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 66     BRAZIL INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 67     MIDDLE EAST & OTHERS INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 68     REST OF LATIN AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 69     AGREEMENTS, COLLABORATION & PARTNERSHIPS (2021-2023)
      • TABLE 70     APPROVALS (2021-2023)
      • TABLE 71     NEW PRODUCT LAUNCH (2021-2023)
      • TABLE 72     OTHERS (2021-2023)
      • TABLE 73     ABBOTT LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
      • TABLE 74     ABBOTT LABORATORIES, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
      • TABLE 75     ABBOTT LABORATORIES, INC: TOTAL REVENUE OF MEDICAL DEVICES, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
      • TABLE 76     ABBOTT LABORATORIES, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
      • TABLE 77     BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2020-2022) ($MN)
      • TABLE 78     BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2020-2022) ($MN)
      • TABLE 79     BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2020-2022) ($MN)
      • TABLE 80     DEXCOM INC: TOTAL REVENUE AND R&D EXPENSES (2020-2022) ($MN)
      • TABLE 81     DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2020-2022) ($MN)
      • TABLE 82     I-SENS, INC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
      • TABLE 83     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
      • TABLE 84     MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q3) ($MN)
      • TABLE 85     MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q3) ($MN)
      • TABLE 86     PHC HOLDINGS: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
      • TABLE 87     PHC HOLDINGS: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q3) ($MN)
      • TABLE 88     PHC HOLDINGS: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q3) ($MN)
      • TABLE 89     ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
      • TABLE 90     ROCHE HOLDINGS AG: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
      • TABLE 91     ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE, BASED ON SUB-SEGMENT, (2020-2022) ($MN)
      • TABLE 92     ROCHE HOLDINGS AG: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
      • TABLE 93     SINOCARE, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)

      LIST OF FIGURES

      • FIGURE 1     GLUCOSE MONITORING GLOBAL MARKET REVENUE AND SHARE, BASED ON REGION (2021-2029) ($MN) (%)
      • FIGURE 2     RESEARCH METHODOLOGY: GLUCOSE MONITORING GLOBAL MARKET
      • FIGURE 3     GLUCOSE MONITORING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     GLUCOSE MONITORING GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     GLUCOSE MONITORING GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     GLUCOSE MONITORING GLOBAL MARKET SEGMENTATION
      • FIGURE 7     PRODUCT MARKET SEGMENTATION
      • FIGURE 8     MARKET DYNAMICS
      • FIGURE 9     GLUCOSE MONITORING GLOBAL MARKET: PATENT FILING, BASED ON MAJOR PLAYERS (2017-2022)
      • FIGURE 10     GLUCOSE MONITORING MARKET: PORTER’S ANALYSIS
      • FIGURE 11     GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 12     SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 13     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 14     NORTH AMERICA SELF MONITORING OF BLOOD GLUCOSE MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 15     EUROPE SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 16     ASIA-PACIFIC SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 17     ROW SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 18     NORTH AMERICA CONTINOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 19     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 20     ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 21     ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
      • FIGURE 22     SELF MONITORING GLUCOSE TEST STRIPS GLOBAL UNITS SOLD, BASED ON REGION AND COUNTRYWISE (2022) (MN)
      • FIGURE 23     CGM SENSORS GLOBAL UNITS SOLD, BASED ON REGION AND COUNTRYWISE (2022) (MN)
      • FIGURE 24     GLOBAL SELF-MONITORING OF BLOOD GLUCOSE (SMBG) MARKET PENETRATION, (2022)
      • FIGURE 25     GLOBAL CONTINUOUS GLUCOSE MONITORING (CGM) MARKET PENETRATION, (2022)
      • FIGURE 26     NORTH AMERICA SMBG MARKET PENETRATION, (2022)
      • FIGURE 27     NORTH AMERICA CGM MARKET PENETRATION, (2022)
      • FIGURE 28     U.S. SMBG MARKET PENETRATION, (2022)
      • FIGURE 29     U.S. CGM MARKET PENETRATION, (2022)
      • FIGURE 30     REST OF N.A. SMBG MARKET PENETRATION, (2022)
      • FIGURE 31     REST OF NA. CGM MARKET PENETRATION, (2022)
      • FIGURE 32     EUROPE SMBG MARKET PENETRATION, (2022)
      • FIGURE 33     EUROPE CGM MARKET PENETRATION, (2022)
      • FIGURE 34     GERMANY SMBG MARKET PENETRATION, (2022)
      • FIGURE 35     GERMANY CGM MARKET PENETRATION, (2022)
      • FIGURE 36     FRANCE SMBG MARKET PENETRATION, (2022)
      • FIGURE 37     FRANCE CGM MARKET PENETRATION, (2022)
      • FIGURE 38     ITALY SMBG MARKET PENETRATION, (2022)
      • FIGURE 39     ITALY CGM MARKET PENETRATION, (2022)
      • FIGURE 40     REST OF E.U. SMBG MARKET PENETRATION, (2022)
      • FIGURE 41     REST OF E.U. CGM MARKET PENETRATION, (2022)
      • FIGURE 42     ASIA-PACIFIC SMBG MARKET PENETRATION, (2022)
      • FIGURE 43     ASIA-PACIFIC CGM MARKET PENETRATION, (2022)
      • FIGURE 44     JAPAN SMBG MARKET PENETRATION, (2022)
      • FIGURE 45     JAPAN CGM MARKET PENETRATION, (2022)
      • FIGURE 46     CHINA SMBG MARKET PENETRATION, (2022)
      • FIGURE 47     CHINA CGM MARKET PENETRATION, (2022)
      • FIGURE 48     INDIA SMBG MARKET PENETRATION, (2022)
      • FIGURE 49     INDIA CGM MARKET PENETRATION, (2022)
      • FIGURE 50     REST OF APAC SMBG MARKET PENETRATION, (2022)
      • FIGURE 51     REST OF APAC CGM MARKET PENETRATION, (2022)
      • FIGURE 52     REST OF THE WORLD SMBG MARKET PENETRATION, (2022)
      • FIGURE 53     REST OF THE WORLD CGM MARKET PENETRATION, (2022)
      • FIGURE 54     BRAZIL SMBG MARKET PENETRATION, (2022)
      • FIGURE 55     BRAZIL CGM MARKET PENETRATION, (2022)
      • FIGURE 56     MIDDLE EAST & OTHERS SMBG MARKET PENETRATION, (2022)
      • FIGURE 57     MIDDLE EAST & OTHERS CGM MARKET PENETRATION, (2022)
      • FIGURE 58     REST OF LATAM SMBG MARKET PENETRATION, (2022)
      • FIGURE 59     REST OF LATAM CGM MARKET PENETRATION, (2022)
      • FIGURE 60     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
      • FIGURE 61     SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 62     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 63     NON-INVASIVE GLUCOSE MONITORS GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 64     LAB BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 65     GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
      • FIGURE 66     URINE BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 67     GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
      • FIGURE 68     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • FIGURE 69     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
      • FIGURE 70     NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 71     NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
      • FIGURE 72     NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
      • FIGURE 73     NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
      • FIGURE 74     U.S. GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS SAMPLE SOURCE & END-USER (2022 VS 2029)($MN)
      • FIGURE 75     U.S. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 76     REST OF NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCT, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 77     REST OF N. A. INVASIVEGLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 78     EUROPE AND INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
      • FIGURE 79     EUROPE SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 80     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 81     EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
      • FIGURE 82     EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
      • FIGURE 83     EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
      • FIGURE 84     GERMANY GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE & END-USER (2022 VS 2029) ($MN)
      • FIGURE 85     GERMANY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 86     ITALY GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS SAMPLE SOURCE & END-USER (2022 VS 2029) ($MN)
      • FIGURE 87     ITALY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 88     FRANCE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 89     FRANCE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 90     REST OF EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 91     REST OF E.U. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 92     ASIA-PACIFIC & INVASIVE GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
      • FIGURE 93     ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 94     ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 95     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
      • FIGURE 96     ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
      • FIGURE 97     ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
      • FIGURE 98     JAPAN GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 99     JAPAN INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 100     CHINA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 101     CHINA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 102     INDIA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 103     INDIA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 104     REST OF APAC GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 105     REST OF APAC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 106     ROW INVASIVE GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
      • FIGURE 107     ROW SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 108     ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 109     ROW GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
      • FIGURE 110     ROW GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
      • FIGURE 111     ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2022 VS 2029) ($MN)
      • FIGURE 112     BRAZIL GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 113     BRAZIL INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 114     MIDDLE EAST & OTHERS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 115     MIDDLE EAST & OTHERS INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 116     REST OF LATIN AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
      • FIGURE 117     REST OF LATIN AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 118     KEY GROWTH STRATEGIES (2021–2023)
      • FIGURE 119     SWOT: ABBOTT LABORATORIES
      • FIGURE 120     SWOT: ARKRAY, INC
      • FIGURE 121     SWOT: BIO-RAD LABORATORIES
      • FIGURE 122     SWOT: DEXCOM INC.
      • FIGURE 123     SWOT: I-SENS, INC.
      • FIGURE 124     SWOT: LIFESCAN
      • FIGURE 125     SWOT: MEDTRONIC, PLC
      • FIGURE 126     SWOT: PHC HOLDINGS (ASCENSIA DIABETES CARE)
      • FIGURE 127     SWOT: ROCHE HOLDINGS AG
      • FIGURE 128     SWOT: SINOCARE

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     77 Elektronika KFT
      • 2     A&T Corporation
      • 3     Abbott Laboratories
      • 4     Abronn fze
      • 5     ACON Laboratories, Inc
      • 6     Adaltis S.r.l
      • 7     Agamatrix, Inc.
      • 8     Ailex Technology Group Co., Ltd
      • 9     Alliance International Co. Ltd
      • 10     Allmedicus Co., Ltd
      • 11     Andesfit System Limited
      • 12     Andon Health Co., Ltd.
      • 13     Apex Biotechnology Corp.
      • 14     Arkray, Inc.
      • 15     Ascensia Diabetes Care Holdings AG
      • 16     AYSET Medical Products
      • 17     B. Braun Melsungen AG
      • 18     Beato Curv
      • 19     Becton Dickinson and Company
      • 20     Beijing Dnurse Technology Co.,Ltd
      • 21     Beijing Yicheng Bioelectronics Technology Co., Ltd.
      • 22     Beurer Gmbh
      • 23     BioCARE Corporation
      • 24     Biochemical Systems International S.p.A.
      • 25     Bioland Technology Ltd.
      • 26     Bionime Corporation (GE)
      • 27     Bioptik Ltd.
      • 28     Bio-Rad Laboratories, Inc
      • 29     BioTelemetry (Philips)
      • 30     Biotest Medical Corporation
      • 31     Bremed Limited
      • 32     Cambridge Sensors Ltd (Microdot)
      • 33     CEI Technology, Inc
      • 34     ChungDo Pharm. Co., Ltd.
      • 35     Cnoga Medical
      • 36     Contec Medical Systems Co., Ltd.
      • 37     Convergent Technologies GmbH & Co. KG
      • 38     CTK Biotech, Inc.
      • 39     Danaher Corporation (Hemocue)
      • 40     Dario Health Corp.
      • 41     Delbio, Inc.
      • 42     Dexcom, Inc
      • 43     Diabetomics, Inc
      • 44     Diagnosis S.A.
      • 45     Dialab GmbH
      • 46     DiaMonTech AG
      • 47     Dr. Morepen
      • 48     Drive DeVilbiss Healthcare
      • 49     EasyMax Diabetes Care
      • 50     EKF Diagnostics
      • 51     e-LinkCare Meditech Co., Ltd.
      • 52     Eps Bio Technology Corp.
      • 53     Eser Healthcare Digital Technology Co., Ltd.
      • 54     Fia Biomed Gmbh
      • 55     Fora Care, Inc
      • 56     General Life Biotechnology Co., Ltd.
      • 57     Genesis Health Technologies, Inc.
      • 58     GlucoMe
      • 59     GlucoRx
      • 60     Glysens Incorporated
      • 61     Goldsite Diagnostics Inc.
      • 62     Guilin Urit Electronic Group Co.,Ltd
      • 63     Haiden Technology Pvt Ltd
      • 64     Hangzhou Sejoy Electronics & Instruments Co., Ltd.
      • 65     Hannox International
      • 66     HMD Biomedical Inc.
      • 67     Hubdic Co Ltd
      • 68     Ihealth Labs, Inc.
      • 69     Ime-Dc Gmbh
      • 70     In4 Technology Corporation
      • 71     Informed Data Systems, Inc. (One Drop)
      • 72      Infinovo Medical Co., Ltd.
      • 73     Intuity Medical, Inc.
      • 74     i-Sens
      • 75     Ixensor Company Ltd.
      • 76     Jiangsu Yuyue Medical Equipment & Supply Co., Ltd (Yuwell)
      • 77     Keto-Mojo Europe B.V.
      • 78     K-Jump Health Co., Ltd.
      • 79     Lepu Medical Technology
      • 80     Life Scan, Inc.
      • 81     Lifotronic Technology Co., Ltd
      • 82     Links Medical Products Inc.
      • 83     Lobeck Medical AG
      • 84     L-Tac MediCare Pte Ltd.
      • 85     Medconn Diagnostics
      • 86     Medisana, GmbH
      • 87     Mediwise (V.S. International)
      • 88     Medsource Ozone Biomedicals Pvt. Ltd.
      • 89     Medtronic, PLC
      • 90     Medtrum Technologies, Inc
      • 91     Menarini Group (A. Menarini Diagnostics s.r.l)
      • 92     Mericonn Technology Co., Ltd.
      • 93     Meril Life Sciences Pvt. Ltd.
      • 94     MHC Medical Products, LLC
      • 95     Microlife AG
      • 96     MicroTech Medical, Inc. (Aidex, Ltd)
      • 97     Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
      • 98     National Diagnostic Products Pty Ltd (Betachek)
      • 99     Nemaura Medical,Inc.
      • 100     Nipro Corporation
      • 101     Nova Biomedical
      • 102     Noviosense BV
      • 103     nu-beca & maxcellent Co.
      • 104     Occuity
      • 105     Ok Biotech Co., Ltd
      • 106     Omron Healthcare
      • 107     Osang HealthCare Co Ltd
      • 108     Palmdoc, Ltd
      • 109     Paramedical srl
      • 110     Pharma Tech Solutions, Inc.
      • 111     Philosys Co., Ltd.
      • 112     Pkvitality
      • 113     Prodigy Diabetes Care, LLC
      • 114     Pulsatom Healthcare Pvt., Ltd.
      • 115     Roche Diagnostics
      • 116     Romed Holland (Van Oostveen Medical B.V.)
      • 117     Sanofi Diabetes
      • 118     SD Biosensor. Inc.
      • 119     Sensa Core Medical Instrumentation Pvt. Ltd.
      • 120     Senseonics, Inc.
      • 121     Shanghai Umitai Medical Technology Co., Ltd
      • 122     Sinocare Inc
      • 123     Taidoc Technology Corporation
      • 124     Terumo
      • 125     Tianjin Empecs Medical Device Co., Ltd.
      • 126     Trinity Biotech, PLC
      • 127     Trividia Health, Inc.,
      • 128     Tyson Bioresearch Inc
      • 129     Visgeneer
      • 130     VivaChek Biotech (Hangzhou) Co., Ltd
      • 131     Volta S.r.l.
      • 132     WaveForm Technologies, Inc.
      • 133     Wellan Tech Co., Limited
      • 134     Wockhardt Ltd
      • 135     Wuhan J.H.Bio-Tech
      • 136     Wuxi BioHermes Bio & Medical Technology Co. Ltd.
      • 137     Ypsomed AG